B. Metzler seel. Sohn & Co. AG Makes New $15.33 Million Investment in McKesson Corporation $MCK

Key Points

• B. Metzler seel. Sohn & Co. AG invested approximately $15.33 million in McKesson during the second quarter, purchasing 20,288 shares. Several other institutional investors also initiated positions, with institutions collectively owning 85.07% of the stock.
• Analyst sentiment remains positive, with 14 Buy ratings and four Holds, resulting in a “Moderate Buy” consensus and an average price target of $973.44.
• McKesson exceeded quarterly expectations with adjusted EPS of $9.93 and revenue of $105.38 billion, while revenue rose 7.7% year over year. The company also increased its quarterly dividend to $0.94 per share, or $3.76 annually.

B. Metzler seel. Sohn & Co. AG bought a new position in shares of McKesson Corporation (NYSE:MCK - Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 20,288 shares of the company's stock, valued at approximately $15,329,000.

Other large investors also recently added to or reduced their stakes in the company. Silvant Capital Management LLC bought a new stake in shares of McKesson during the 2nd quarter valued at about $5,190,000. Fairtree Asset Management Pty Ltd purchased a new stake in shares of McKesson during the 2nd quarter valued at $2,385,000. D L Carlson Investment Group Inc. bought a new position in McKesson in the second quarter valued at $3,417,000. Portfolio Design Labs LLC bought a new stake in McKesson during the second quarter worth about $1,969,000. Finally, Hara Capital LLC purchased a new position in shares of McKesson during the 2nd quarter valued at about $57,000. Institutional investors own 85.07% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have commented on MCK shares. TD Cowen increased their price target on shares of McKesson from $989.00 to $1,006.00 and gave the company a "buy" rating in a research report on Thursday, August 6th. Weiss Ratings downgraded McKesson from a "buy (b)" rating to a "buy (b-)" rating in a report on Tuesday, July 7th. Evercore reiterated an "outperform" rating on shares of McKesson in a research report on Thursday, August 6th. Royal Bank Of Canada initiated coverage on shares of McKesson in a report on Wednesday. They set a "sector perform" rating and a $845.00 price target for the company. Finally, Citigroup boosted their price objective on shares of McKesson from $945.00 to $1,000.00 and gave the company a "buy" rating in a research report on Friday, July 24th. Fourteen investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $973.44.

Insider Buying and Selling at McKesson

In other McKesson news, Director Bradley E. Lerman sold 301 shares of McKesson stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $892.33, for a total value of $268,591.33. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Thomas L. Rodgers sold 2,388 shares of the firm's stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $761.09, for a total transaction of $1,817,482.92. Following the sale, the executive vice president directly owned 3,090 shares of the company's stock, valued at $2,351,768.10. This trade represents a 43.59% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 29,049 shares of company stock valued at $22,530,626 in the last ninety days. Corporate insiders own 0.06% of the company's stock.

McKesson Price Performance

Shares of NYSE MCK opened at $841.21 on Friday. McKesson Corporation has a 1 year low of $673.38 and a 1 year high of $999.00. The company's 50-day moving average is $819.40 and its 200 day moving average is $843.73. The stock has a market capitalization of $98.08 billion, a P/E ratio of 22.51, a P/E/G ratio of 1.68 and a beta of 0.30.

McKesson (NYSE:MCK - Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported $9.93 earnings per share for the quarter, topping analysts' consensus estimates of $9.56 by $0.37. McKesson had a negative return on equity of 253.21% and a net margin of 1.12%.The firm had revenue of $105.38 billion for the quarter, compared to the consensus estimate of $103.88 billion. During the same quarter in the prior year, the business earned $8.26 EPS. The business's revenue for the quarter was up 7.7% on a year-over-year basis. McKesson has set its FY 2027 guidance at 44.200-45.000 EPS. Research analysts anticipate that McKesson Corporation will post 44.65 earnings per share for the current year.

McKesson Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 1st. Stockholders of record on Tuesday, September 1st will be given a $0.94 dividend. The ex-dividend date of this dividend is Tuesday, September 1st. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.4%. This is an increase from McKesson's previous quarterly dividend of $0.82. McKesson's payout ratio is presently 10.06%.

About McKesson

McKesson Corporation NYSE: MCK is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company's core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.

Want to see what other hedge funds are holding MCK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for McKesson Corporation (NYSE:MCK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source